ATASOY, BESTE MELEK2022-03-142022-03-142011-010923-7534https://hdl.handle.net/11424/244258Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.enginfo:eu-repo/semantics/openAccesschemotherapycombined modality treatmentnon-Hodgkin's lymphomaprognostic factorsradiotherapythyroid lymphomaB-CELL LYMPHOMANON-HODGKINS-LYMPHOMAMALIGNANT-LYMPHOMALOCALIZED INTERMEDIATEONCOLOGY-GROUPGLANDRADIOTHERAPYCHEMOTHERAPYTHERAPYCHOParticleWOS:00028541480002310.1093/annonc/mdq31020587509